MBX Biosciences, Inc.

Parabolica Therapeutics develops proprietary peptide conjugation technologies focused on obesity and other metabolic conditions. The company researches and advances therapeutic programs through its scientific approach.

Amolyt Pharma is a biotechnology company focused on developing peptide therapeutics for rare endocrine and metabolic diseases. Its lead program, eneboparatide, is being developed for chronic hypoparathyroidism, serving patients with serious hormone-related disorders and the clinicians who treat them.

Vogenx, Inc.VOGX · BiotechRaleigh, United States

69% matchPublic

Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.